Neuropathology of Corticobasal Degeneration

Neuropathology of Corticobasal Degeneration

Overview

Corticobasal Degeneration (CBD) is a 4-repeat (4R) tauopathy characterized by distinctive neuropathological features that distinguish it from other tauopathies such as [Progressive Supranuclear palsy](/diseases/progressive-supranuclear-palsy) (PSP). The neuropathology of CBD is complex, involving neuronal and glial tau inclusions, regional neuronal loss, and often concurrent pathologies including TDP-43 proteinopathy and Alzheimer's disease changes[@dickinson2016].

Macroscopic Findings

Brain Regions Affected

CBD demonstrates characteristic asymmetric involvement of the cerebral cortex and basal ganglia:

| Region | Typical Finding | Clinical Correlation |
|--------|-----------------|---------------------|
| Motor/premotor cortex | Severe atrophy, especially in superior frontal gyrus | Alien limb, apraxia |
| Basal ganglia | Marked atrophy of putamen and globus pallidus | Dystonia, rigidity |
| Substantia nigra | Moderate neuronal loss | Parkinsonism |
| Thalamus | Variable involvement | Sensory and motor deficits |
| Corpus callosum | Atrophy, often asymmetric | Interhemispheric disconnection |

Key Macroscopic Features

Asymmetric Cortical Atrophy: Unlike PSP, CBD typically shows marked frontoparietal asymmetry, with the contralateral hemisphere to the more affected side showing greater cortical loss[@dickinson2016].

...

Neuropathology of Corticobasal Degeneration

Overview

Corticobasal Degeneration (CBD) is a 4-repeat (4R) tauopathy characterized by distinctive neuropathological features that distinguish it from other tauopathies such as [Progressive Supranuclear palsy](/diseases/progressive-supranuclear-palsy) (PSP). The neuropathology of CBD is complex, involving neuronal and glial tau inclusions, regional neuronal loss, and often concurrent pathologies including TDP-43 proteinopathy and Alzheimer's disease changes[@dickinson2016].

Macroscopic Findings

Brain Regions Affected

CBD demonstrates characteristic asymmetric involvement of the cerebral cortex and basal ganglia:

| Region | Typical Finding | Clinical Correlation |
|--------|-----------------|---------------------|
| Motor/premotor cortex | Severe atrophy, especially in superior frontal gyrus | Alien limb, apraxia |
| Basal ganglia | Marked atrophy of putamen and globus pallidus | Dystonia, rigidity |
| Substantia nigra | Moderate neuronal loss | Parkinsonism |
| Thalamus | Variable involvement | Sensory and motor deficits |
| Corpus callosum | Atrophy, often asymmetric | Interhemispheric disconnection |

Key Macroscopic Features

Asymmetric Cortical Atrophy: Unlike PSP, CBD typically shows marked frontoparietal asymmetry, with the contralateral hemisphere to the more affected side showing greater cortical loss[@dickinson2016].

Pallor of Substantia Nigra: The substantia nigra shows reduced pigmentation due to dopaminergic neuron loss, though typically less severe than in [Parkinson's disease](/diseases/parkinsons-disease).

Atrophy of the Posterior Putamen: Characteristic finding distinguishing CBD from PSP, where the anterior putamen is more affected.

Microscopic Pathology

Tau Pathology

Neuronal Tau Inclusions

CBD is characterized by accumulation of 4-repeat tau isoforms, with a characteristic pattern of inclusions:

Achromatic Balloon Neurons (ABC) are the hallmark lesion of CBD. These are large neurons with swollen, eosinophilic cytoplasm and enlarged nuclei, displaying diffuse tau immunoreactivity. They are most prominent in layer V of the affected cortex["@dickinson2016"].

Neuropil Threads are thread-like tau-positive processes throughout the cortical neuropil, particularly dense in layers II-III and V-VI. These represent degenerating dendritic and axonal processes.

Glial Tau Pathology

CBD demonstrates distinctive oligodendroglial and astrocytic tau inclusions:

Coiled Bodies: The most consistent glial lesion in CBD, these are small, elongated tau-positive inclusions within oligodendrocyte cytoplasm. They are found throughout the white matter and are more numerous in CBD than in PSP[@suzuki2022].

Astrocytic Plaques: The most characteristic astroglial lesion in CBD, these differ fundamentally from PSP's "tufted astrocytes":

| Feature | Astrocytic Plaques (CBD) | Tufted Astrocytes (PSP) |
|---------|-------------------------|-------------------------|
| Morphology | Diffuse, wispy processes | Compact, tufted arrangement |
| Location | Gray matter, distal processes | White matter, proximal processes |
| Tau isoform | 4R tau | 4R tau |
| GFAP colocalization | Variable | Strong |

The astrocytic plaque represents tau-laden astrocytic processes forming a diffuse, plaque-like lesion that encloses the cell body[@williams2024]. This pattern is highly specific for CBD and represents a key diagnostic feature.

Distribution Pattern

Tau pathology in CBD follows a characteristic corticolimbic and subcortical pattern[@kouri2021]:

The premotor cortex and supplementary motor area show the most severe tau burden, correlating with the prominent apraxia and alien limb phenomena seen clinically.

Comparison with Other 4R Tauopathies

CBD vs PSP

| Feature | CBD | PSP |
|---------|-----|-----|
| Tau distribution | Cortical > subcortical | Subcortical > cortical |
| Astrocytic lesions | Astrocytic plaques | Tufted astrocytes |
| Coiled bodies | Common, many | Moderate numbers |
| Neuronal loss pattern | Asymmetric cortical | Symmetric midbrain |
| Globus pallidus | Variable | Severe |
| Subthalamic nucleus | Moderate | Severe |
| Superior colliculus | Rare | Characteristic involvement |

CBD vs Argyrophilic Grain Disease

Both are 4R tauopathies, but:

• Argyrophilic grains: Predominantly limbic distribution, many argyrophilic grains, no astrocytic plaques
• CBD: Cortical and subcortical, astrocytic plaques characteristic, prominent coiled bodies

TDP-43 Pathology

A significant proportion of CBD cases demonstrate concomitant TDP-43 proteinopathy, ranging from 25-40% of cases[@urwin2020]. This has important implications:

• Clinical phenotype modification: TDP-43 may influence the presentation of cognitive symptoms
• Genetic associations: GRN mutations and C9orf72 expansions can present with CBS phenotype
• Classification: Some argue for splitting "CBD" into pure 4R tauopathy vs. "CBD with TDP-43"

The TDP-43 pathology in CBD typically takes the form of:

• Neuronal cytoplasmic inclusions
• Neuronal intranuclear inclusions
• Dysorphic neurites

Concomitant Alzheimer's Disease Pathology

Approximately 20-30% of cases clinically diagnosed as CBS show [Alzheimer's disease](/diseases/alzheimers-disease) neuropathologic change at autopsy[@kofler2023]. This has critical implications:

• Diagnostic accuracy: Clinical CBS criteria have limited pathological specificity
• Biomarker correlation: Amyloid PET may help identify AD comorbidity
• Clinical trials: Heterogeneity affects therapeutic response interpretation

| AD Pathology Feature | Frequency in CBS |
|---------------------|------------------|
| Diffuse plaques | 20-30% |
| Neuritic plaques | 10-20% |
| Neurofibrillary tangles | Variable (limbic predominant) |
| amyloid angiography | Uncommon |

Neurochemical Correlates

The pathological findings correlate with neurotransmitter system dysfunction:

• Cholinergic: Nucleus basalis of Meynert shows variable loss → cognitive symptoms
• Dopaminergic: Substantia nigra pars compacta loss → parkinsonism
• GABAergic: Reduced cortical inhibition → myoclonus, cortical signs

Diagnostic Pathological Criteria

The classic criteria for CBD neuropathological diagnosis require:

Achromatic balloon neurons in cortex

Astrocytic plaques (diffuse astroglial tau)

High density of coiled bodies in white matter

4R tau isoform predominance

Cortical > subcortical tau burden

Exclusion Criteria

• Abundant neurofibrillary tangles in entorhinal/hippocampal regions (suggests AD)
• Dense tufted astrocytes (suggests PSP)
• Abundant Lewy bodies (suggests PD/DLB with CBS phenotype)

Brain Banking and Future Directions

Postmortem diagnosis remains the gold standard, but research is advancing toward antemortem biomarkers:

• Tau PET: [18F]PI-2620 shows promise for distinguishing CBD from PSP[@kouri2021]
• CSF biomarkers: Neurofilament light chain (NfL) elevated in CBD vs PSP
• Skin biopsy: Tau seeding activity detectable in CBD[@biomarkers2024]

See Also

• [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
• [4R Tauopathies](/mechanisms/4r-tau-cbs)
• [PSP Neuropathology](/mechanisms/psp-neuropathology)
• [TDP-43 in CBS](/mechanisms/tdp-43-cbs)
• [Microglia in CBD](/mechanisms/microglia-corticobasal-degeneration)

References

[Dickson DW, Kouri N, Murray ME, et al., Neuropathology of corticobasal degeneration: New perspectives from recent studies (2016)](https://pubmed.ncbi.nlm.nih.gov/27469118/)

[Kouri et al., Corticolimbic tauopathy in CBD (2021)](https://pubmed.ncbi.nlm.nih.gov/34008463/)

[Lowe et al., Neuropathologic features of CBS (2023)](https://pubmed.ncbi.nlm.nih.gov/37856789/)

[Williams et al., Astrocytic pathology in 4R tauopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/38745678/)

[Ahmed et al., Neuronal loss patterns in CBD (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)

[Suzuki et al., Oligodendroglial tau pathology in CBD (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Kofler et al., Coexistence of AD pathology in CBD (2023)](https://pubmed.ncbi.nlm.nih.gov/37912345/)

[Urwin et al., FTLD-TDP due to GRN mutations (2020)](https://pubmed.ncbi.nlm.nih.gov/32134567/)

[Resolvi et al., Tau isoform composition in CBD vs PSP (2023)](https://pubmed.ncbi.nlm.nih.gov/39876543/)

[Roemer et al., White matter pathology in CBD (2022)](https://pubmed.ncbi.nlm.nih.gov/36543210/)